These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36048168)

  • 1. Identification and characterization of mercaptopyrimidine-based small molecules as inhibitors of nonhomologous DNA end joining.
    Ray U; Gopinatha VK; Sharma S; Goyary L; Choudhary B; Mantelingu K; Rangappa KS; Raghavan SC
    FEBS J; 2023 Feb; 290(3):796-820. PubMed ID: 36048168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
    Vartak SV; Swarup HA; Gopalakrishnan V; Gopinatha VK; Ropars V; Nambiar M; John F; Kothanahally SKS; Kumari R; Kumari N; Ray U; Radha G; Dinesh D; Pandey M; Ananda H; Karki SS; Srivastava M; Charbonnier JB; Choudhary B; Mantelingu K; Raghavan SC
    FEBS J; 2018 Nov; 285(21):3959-3976. PubMed ID: 30230716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics.
    Ray U; Raul SK; Gopinatha VK; Ghosh D; Rangappa KS; Mantelingu K; Raghavan SC
    Mol Carcinog; 2020 Jun; 59(6):618-628. PubMed ID: 32189406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCR7, a potent cancer therapeutic agent and a biochemical inhibitor of nonhomologous DNA end-joining.
    Manjunath M; Choudhary B; Raghavan SC
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1341. PubMed ID: 33496064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV.
    Greco GE; Matsumoto Y; Brooks RC; Lu Z; Lieber MR; Tomkinson AE
    DNA Repair (Amst); 2016 Jul; 43():18-23. PubMed ID: 27235626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SCR7, an inhibitor of NHEJ can sensitize tumor cells to ionization radiation.
    Gopalakrishnan V; Sharma S; Ray U; Manjunath M; Lakshmanan D; Vartak SV; Gopinatha VK; Srivastava M; Kempegowda M; Choudhary B; Raghavan SC
    Mol Carcinog; 2021 Sep; 60(9):627-643. PubMed ID: 34192388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing.
    Vartak SV; Raghavan SC
    FEBS J; 2015 Nov; 282(22):4289-94. PubMed ID: 26290158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression.
    Srivastava M; Nambiar M; Sharma S; Karki SS; Goldsmith G; Hegde M; Kumar S; Pandey M; Singh RK; Ray P; Natarajan R; Kelkar M; De A; Choudhary B; Raghavan SC
    Cell; 2012 Dec; 151(7):1474-87. PubMed ID: 23260137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
    Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
    Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced efficacy of pluronic copolymer micelle encapsulated SCR7 against cancer cell proliferation.
    John F; George J; Vartak SV; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Macromol Biosci; 2015 Apr; 15(4):521-34. PubMed ID: 25515310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of XLF and PAXX prevents DNA double-strand break repair by non-homologous end joining in lymphocytes.
    Hung PJ; Chen BR; George R; Liberman C; Morales AJ; Colon-Ortiz P; Tyler JK; Sleckman BP; Bredemeyer AL
    Cell Cycle; 2017 Feb; 16(3):286-295. PubMed ID: 27830975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the DNA double-strand break repair and its therapeutic implications.
    Ray U; Raghavan SC
    DNA Repair (Amst); 2021 Oct; 106():103177. PubMed ID: 34325086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XLF/Cernunnos: An important but puzzling participant in the nonhomologous end joining DNA repair pathway.
    Menon V; Povirk LF
    DNA Repair (Amst); 2017 Oct; 58():29-37. PubMed ID: 28846869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of Mycobacterium marinum Nonhomologous DNA End Joining Pathway in
    Zhang WW; Wright DG; Harrison L; Matlashewski G
    mSphere; 2022 Jun; 7(3):e0015622. PubMed ID: 35695492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAXX and XLF DNA repair factors are functionally redundant in joining DNA breaks in a G1-arrested progenitor B-cell line.
    Kumar V; Alt FW; Frock RL
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10619-24. PubMed ID: 27601633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pluronic copolymer encapsulated SCR7 as a potential anticancer agent.
    John F; George J; Srivastava M; Hassan PA; Aswal VK; Karki SS; Raghavan SC
    Faraday Discuss; 2015; 177():155-61. PubMed ID: 25608025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NHEJ Contributes to the Fast Repair of Radiation-induced DNA Double-strand Breaks at Late Prophase I Telomeres.
    Ahmed EA; Rosemann M; Scherthan H
    Health Phys; 2018 Jul; 115(1):102-107. PubMed ID: 29787435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.
    Murmann-Konda T; Soni A; Stuschke M; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role for Artemis nuclease in the repair of radiation-induced DNA double strand breaks by alternative end joining.
    Moscariello M; Wieloch R; Kurosawa A; Li F; Adachi N; Mladenov E; Iliakis G
    DNA Repair (Amst); 2015 Jul; 31():29-40. PubMed ID: 25973742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
    Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
    Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.